Company

MitoSense, Inc.

MitoSense develops mitochondrial transplantation technology for neurodegenerative diseases.

About

MitoSense is developing Mitochondria Organelle Transplantation, a technology intended to restore mitochondria in cells and address diseases including ALS, Alzheimer's, and Parkinson's. Founded in 2019, the company is based in Virginia. It raised USD 3.5 million in seed funding in January 2024, led by Caydan Capital Partners.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in